Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58096 | 0.82 | HDAC1 (0.44) | CA1CA2CA9CA3HDAC1 | |
| SCHEMBL18076660 | 0.82 | CA1 (0.44) | CA1CA2CA9CA3ALDH1A1 | |
| SCHEMBL14880913 | 0.75 | CA1 (0.52) | CA1CA2CA9CA3HDAC1 | |
| SCHEMBL20828819 | 0.75 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL18426752 | 0.75 | CA1 (0.39) | CA1CA2CA9ALDH1A1ALOX15 | |
| SCHEMBL31441248 | 0.75 | CA1 (0.39) | CA1CA2CA9HDAC1HDAC6 | |
| SCHEMBL19723645 | 0.75 | CA1 (0.54) | CA1CA2CA9CA3ALDH1A1 | |
| SCHEMBL1639935 | 0.75 | CA1 (0.54) | CA1CA2CA9CA3HDAC1 | |
| SCHEMBL231997 | 0.75 | CA1 (0.39) | CA1CA2CA9HDAC1HDAC6 | |
| SCHEMBL25188992 | 0.71 | HDAC1 (0.33) | HDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562000-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12281102-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119630652-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2024022487-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-116157393-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4165023-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4165022-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| WO-2009153307-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153307-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281102-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | CA1 4755/4885CA2 4619/4885CA9 3578/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | CA1 4833/4885CA2 4861/4885CA9 3851/4885 |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CA1 4858/4885CA2 4623/4885CA9 4135/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | CA1 971/4885CA2 809/4885CA9 1399/4885 |
| US-20100029729-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CA1 3853/4885CA2 1833/4885CA9 3091/4885 |
| US-20100010053-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CA1 3853/4885CA2 1833/4885CA9 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.